Your search history is turned on.
Date: April 3, 2024 Jurisdictions: British Columbia
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDAs accelerated approval pathway $31 mil...
Date: March 27, 2024 Jurisdictions: British Columbia
Counsel Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab SAN DIEGO, March 27, 2024/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new solid tumor can...
Date: February 14, 2024 Jurisdictions: British Columbia
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Comm...
Microsoft Word - KTRA Q2 2024 Results Release 02-09-2024 draft v4 Clean.docx Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update SAN DIEGO, February 14, 2024/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new solid...
KTRA_10Q_20231231 FINAL AS FILED.pdf Exhibit 31.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Robert E. Hoffman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Kintara Therapeutics, Inc.; 2. Based on my know...
KTRA_10Q_20231231 FINAL AS FILED.pdf Exhibit 31.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Robert E. Hoffman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Kintara Therapeutics, Inc.; 2. Based on my know...
KTRA_10Q_20231231 FINAL AS FILED.pdf 18 Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations. This Managements Discussion and Analysis (MD&A) contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, which represent our projections, estimates, expectations, or beli...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...
Date: February 12, 2024 Jurisdictions: British Columbia
Counsel Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer - 15-patient Open Label Study to Confirm Planned Dose and Optimized Study Design Leading to a Phase 3 Clinical Trial in CMBC Patients - SAN DIEGO, February 12, 2024/P...
Date: December 7, 2023 Jurisdictions: British Columbia
Microsoft Word - KTRA Strategic Alternatives - LT Comments LS Edits (clean).docx Kintara Therapeutics Announces Review of Strategic Alternatives - Ladenburg Thalmann Hired as Financial advisor - SAN DIEGO, December 7, 2023/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development...